SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 12.17 |
| Enterprise Value ($M) | -9.22 |
| Book Value ($M) | 15.68 |
| Book Value / Share | 0.34 |
| Price / Book | 0.78 |
| NCAV ($M) | 14.45 |
| NCAV / Share | 0.31 |
| Price / NCAV | 0.84 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.76 |
| Return on Assets (ROA) | -1.04 |
| Return on Equity (ROE) | -1.70 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.58 |
| Current Ratio | 2.58 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 24.25 |
| Assets | 25.47 |
| Liabilities | 9.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -51.78 |
| Net Income | -44.58 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -47.58 |
| Cash from Investing | -0.10 |
| Cash from Financing | 61.41 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Nantahala Capital Management, LLC | 5.73 | ||
| 13G/A | Lytton Laurence W | 8.80 | -9.90 | |
| 13G/A | Rosalind Advisors, Inc. | 9.90 | 103.53 | |
| 13G/A | Hirschman Orin | 4.90 | -24.04 | |
| 13G/A | ADAR1 Capital Management, LLC | 8.51 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 117,340 | 420,522 | 27.90 | |
| 89,271 | 276,536 | 32.28 | |
| 139,626 | 518,365 | 26.94 | |
| 112,739 | 369,729 | 30.49 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CKPT – Checkpoint Therapeutics, Inc. | CLDX – Celldex Therapeutics, Inc. |
| CLNN – Clene Inc. | CMPX – Compass Therapeutics, Inc. |
| CNSP – CNS Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io